Last reviewed · How we verify

Cerebrolysin infusion

Clinical Institute of the Brain, Russia · FDA-approved active Small molecule

Cerebrolysin is a standardized peptide and amino acid mixture derived from porcine brain that promotes neuroprotection and neuroplasticity through multiple mechanisms including neurotrophic factor activity and metabolic support.

Cerebrolysin is a neurotrophic drug developed by the Clinical Institute of the Brain in Russia. It is not approved by the FDA and is primarily used off-label for various neurological conditions. The drug is a mixture of low molecular weight peptides and amino acids derived from pig brain tissue. It is believed to have neuroprotective and neurorestorative properties, but its efficacy and safety are still under investigation. Cerebrolysin is administered via intravenous infusion and is used in several countries outside the United States.

At a glance

Generic nameCerebrolysin infusion
Also known asCerebrolysin
SponsorClinical Institute of the Brain, Russia
Drug classNeuropeptide mixture
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

The drug contains low-molecular-weight peptides and free amino acids that are thought to mimic the action of endogenous neurotrophic factors, enhancing neuronal survival and promoting synaptic plasticity. It is proposed to work through multiple pathways including anti-inflammatory effects, antioxidant activity, and enhancement of cerebral metabolism. The exact molecular targets remain incompletely characterized, but the preparation is believed to support neuronal repair and regeneration in damaged brain tissue.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: